Glucose News and Research

RSS

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

Neighborhood may be a modifiable risk factor for diabetes

Individuals living in neighborhoods conducive to physical activity and providing access to healthy foods may have a lower risk of developing type 2 diabetes in a five-year period, according to a report in the October 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Oct 2009

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

According to new research from the Monell Center and the Mount Sinai School of Medicine, certain common herbicides and lipid-lowering fibrate drugs act in humans to block T1R3, a nutrient-sensing taste receptor also present in intestine and pancreas.

12 Oct 2009

New Everyware Medical Gateway solution to remotely monitor treatment for diabetic patients

Eurotech Group, a leading supplier of embedded technologies, products, and systems, announces today the Everyware(TM) Medical Gateway designed to help physicians remotely monitor and adjust the treatment of their diabetes patients.

8 Oct 2009

Sanvita CBGM acquires certain assets of CCS Medical's subsidiary Sanvita

Nova Biomedical Corporation, a leading developer of whole blood analyzers, today announced that the company's independent, wholly owned subsidiary, Sanvita CBGM, LLC, has completed the acquisition of certain assets of Sanvita, Inc., a subsidiary of CCS Medical, Inc.

8 Oct 2009

CHEO researchers identify protein that inhibits insulin production

One of the biggest mysteries about diabetes is why specialized cells in the pancreas stop secreting insulin, which the body needs in order to store glucose from food. A team from the Children's Hospital of Eastern Ontario (CHEO) Research Institute has identified a protein that inhibits insulin production in mice - work that offers a new way of understanding, and perhaps of one day treating, both Type 1 and Type 2 diabetes.

8 Oct 2009

Diabetech and Cinterion Wireless Modules announce their collaboration on fourth generation GlucoMON platform

Cinterion Wireless Modules, the global leader in cellular machine-to-machine (M2M) communication modules, and Diabetech, the leader in patient-centric health care programs, today announced their collaboration on the fourth generation GlucoMON® platform, the world’s easiest-to-use wireless diabetes management system designed to help the over 220 million people worldwide struggling to manage the global diabetes and pre-diabetes pandemic.

7 Oct 2009

Low levels of ROS might protect us from diabetes, says study

We've all heard about the damage that reactive oxygen species (ROS) - aka free radicals - can do to our bodies and the sales pitches for antioxidant vitamins, skin creams or "superfoods" that can stop them. In fact, there is considerable scientific evidence that chronic ROS production within cells can contribute to human diseases, including insulin resistance and type 2 diabetes.

7 Oct 2009

More research required to determine efficacy of Chinese herbal medicines in preventing diabetes

More research is required to establish whether Chinese herbal medicines can reduce the likelihood of developing diabetes, according to Cochrane Researchers. Although herbal medicines are widely used in Asian countries to treat pre-diabetes (impaired glucose tolerance or IGT), the precursor of the disease, researchers say there is still not enough hard scientific evidence to confidently recommend their use.

7 Oct 2009

U.S. market for diabetes drugs, devices and monitoring systems to reach over $55 billion by 2016

According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for diabetes drugs, devices and monitoring systems will reach over $55 billion by 2016, tripling in value.

6 Oct 2009

Resveratrol may help improve diet-induced diabetes

Resveratrol, a molecule found in red grapes, has been shown to improve diabetes when delivered orally to rodents. Until now, however, little has been known about how these beneficial changes are mediated in the body.

6 Oct 2009

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.

5 Oct 2009

Study finds that visual impairment in T1D patients may be decreasing

People diagnosed with type 1 diabetes (T1D) in recent years are less likely to develop diabetes-related vision loss than those diagnosed in earlier years, says a new study funded by the National Eye Institute, a division of the National Institutes of Health. Forecasts of visual impairment prevalence in T1D patients may need to be amended, the researchers suggest, since current predictions assume that the earlier incidence rates will continue.

3 Oct 2009

New study shows that NovoMix 30 is effective for type 2 diabetes patients who are to start on insulin

Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) shows that type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix® 30 (biphasic insulin aspart) achieve a significantly greater HbA1c reduction compared to patients starting with a daily injection of insulin glargine.

3 Oct 2009

Self-monitoring of blood glucose helps patients with diabetes to manage their disease better

Self-monitoring of blood glucose (SMBG) enables those with diabetes to modify their behavior, adjust their medicine and understand their disease to better manage it, according to a recent study, published by SAGE in The Diabetes Educator. The research looked at "paired testing," a self-monitored testing both before and after specific events, to evaluate whether it could assist the patient in making better health and food choice decisions over time.

3 Oct 2009

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.

3 Oct 2009

Array BioPharma to present poster on ARRY-403 glucokinase activator

Array BioPharma Inc. today announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria.

2 Oct 2009

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

AFRESA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, showed no significant changes in pulmonary function and sustained glycemic control in adult patients with type 2 diabetes over four years of continuous treatment, according to data presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes.

2 Oct 2009

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.

1 Oct 2009

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

Glucose News and Research

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Neighborhood may be a modifiable risk factor for diabetes

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

New Everyware Medical Gateway solution to remotely monitor treatment for diabetic patients

Sanvita CBGM acquires certain assets of CCS Medical's subsidiary Sanvita

CHEO researchers identify protein that inhibits insulin production

Diabetech and Cinterion Wireless Modules announce their collaboration on fourth generation GlucoMON platform

Low levels of ROS might protect us from diabetes, says study

More research required to determine efficacy of Chinese herbal medicines in preventing diabetes

U.S. market for diabetes drugs, devices and monitoring systems to reach over $55 billion by 2016

Resveratrol may help improve diet-induced diabetes

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Study finds that visual impairment in T1D patients may be decreasing

New study shows that NovoMix 30 is effective for type 2 diabetes patients who are to start on insulin

Self-monitoring of blood glucose helps patients with diabetes to manage their disease better

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Array BioPharma to present poster on ARRY-403 glucokinase activator

Clinical study results demonstrate the efficacy of AFRESA inhalation powder

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News